PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022

News provided by

Jul 23, 2013, 03:04 ET

NEW YORK, July 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p01557315/PharmaPoint-Psoriasis---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022". There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

The US is the largest PsO market, although it does not have the highest prevalence of the disease. GlobalData estimates that the US generated approximate sales in 2012. J&J's Stelara has been impressive since launching in 2009, and claimed close the patient share compared with its company counterpart, Remicade, which only drew less in 2012. Since Stelara's cost per day is the highest of the biologics, which is three times that of Remicade, it did not take a lot of patient share to generate comfortable annual sales close in 2012.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the US.

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 15
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 20
4.2 US 25
4.2.1 Diagnosis 25
4.2.2 Clinical Practice 26
5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 30
5.3 Product Profiles – Major Brands 31
5.3.1 Enbrel (etanercept) 31
5.3.2 Humira (adalimumab) 36
5.3.3 Remicade (infliximab) 41
5.3.4 Stelara (ustekinumab) 47
5.3.5 Taclonex (calcipotriene hydrate and betamethasone dipropionate) 52
5.3.6 Methotrexate Sodium (numerous generic names) 56
5.3.7 Minor Therapeutic Drug Classes Used in Psoriasis 60
5.3.8 Non-Pharmacological Therapy 61
6 Opportunity and Unmet Need 63
6.1 Overview 63
6.2 Unmet Needs 64
6.2.1 Improved Drug Safety and Efficacy Profiles 64
6.2.2 Biomarkers for Predicting Remission 65
6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 65
6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 66
6.2.5 An Effective Biologic/Systemic Topical Therapy 66
6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 67
6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 67
6.3 Opportunities 68
6.4 Unmet Needs Gap Analysis 68
6.4.1 Predictive Tools for Diagnosis and Treatment 69
6.4.2 Target Specificity 69
6.4.3 Topical Biologic/Systemic Therapeutic Options 70
6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 70
7 Pipeline Assessment 71
7.1 Overview 71
7.2 Promising Drugs in Clinical Development 72
7.2.1 Brodalumab (AMG 827) 74
7.2.2 Secukinumab (AIN457) 80
7.2.3 Ixekizumab (LY2439821) 85
7.2.4 Tildrakizumab (MK-3222/SCH-900222) 90
7.2.5 Xeljanz (tofacitinib) 94
7.2.6 Apremilast (CC-10004) 100
7.2.7 Phase II Pipeline Products 105
7.2.8 Phase I Pipeline Products 107
7.2.9 Biosimilars Pipeline Products 108
8 Market Outlook 111
8.1 United States 111
8.1.1 Forecast 111
8.1.2 Key Events 115
8.1.3 Drivers and Barriers 115
9 Appendix 118
9.1 Bibliography 118
9.2 Abbreviations 124
9.3 Methodology 128
9.4 Forecasting Methodology 128
9.4.1 Diagnosed Psoriasis Patients 128
9.4.2 Percent Drug-Treated Patients 129
9.4.3 Drugs Included in Each Therapeutic Class 129
9.4.4 Launch and Patent Expiry Dates 130
9.4.5 General Pricing Assumptions 131
9.4.6 Individual Drug Assumptions 132
9.4.7 Generic Erosion 136
9.4.8 Pricing of Pipeline agents 136
9.5 Physicians and Specialists Included in this Study 137
9.6 Primary Research – Prescriber Survey 138
9.7 About the Authors 139
9.7.1 Analysts 139
9.7.2 Global Head of Healthcare 140
9.8 About GlobalData 141
9.9 Disclaimer 141

1.1 List of Tables

Table 1: Immune Cells Involved in Lesions 15
Table 2: Symptoms of Psoriasis 18
Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis 22
Table 4: Treatment Guidelines for Psoriasis 23
Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2012 24
Table 6: Leading Treatments for Psoriasis, 2013 30
Table 7: Product Profile – Enbrel 32
Table 8: Enbrel SWOT Analysis, 2013 35
Table 9: Product Profile – Humira 37
Table 10: Humira SWOT Analysis, 2013 40
Table 11: Product Profile – Remicade 42
Table 12: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26 43
Table 13: Safety Results (AEs) of RESTORE1 Trial of Remicade vs. MTX at Week 16 44
Table 14: Remicade SWOT Analysis, 2013 46
Table 15: Product Profile – Stelara 48
Table 16: Stelara SWOT Analysis, 2013 51
Table 17: Product Profile – Taclonex 53
Table 18: Taclonex SWOT Analysis, 2013 55
Table 19: Product Profile – Methotrexate 57
Table 20: Methotrexate SWOT Analysis, 2013 59
Table 21: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2013 60
Table 22: Overall Unmet Needs in Psoriasis – Current Level of Attainment 64
Table 23: Clinical Unmet Needs in Psoriasis – Gap Analysis, 2013 69
Table 24: Psoriasis – Phase Pipeline, 2013 72
Table 25: Comparison of Therapeutic Classes in Development for Psoriasis, 2013 73
Table 26: Product Profile – Brodalumab 75
Table 27: Efficacy Results of Phase II Study of Brodalumab vs. Placebo at Week 12 76
Table 28: Brodalumab SWOT Analysis, 2013 79
Table 29: Product Profile – Secukinumab 81
Table 30: Secukinumab SWOT Analysis, 2013 84
Table 31: Product Profile – Ixekizumab 85
Table 32: Efficacy Results of Phase II Study of Ixekizumab vs. Placebo at Week 12 86
Table 33: Ixekizumab SWOT Analysis, 2013 89
Table 34: Product Profile – Tildrakizumab 91
Table 35: Tildrakizumab SWOT Analysis, 2013 93
Table 36: Product Profile – Xeljanz 95
Table 37: Xeljanz SWOT Analysis, 2013 99
Table 38: Product Profile – Apremilast 101
Table 39: Efficacy Results of Phase IIb Study of Apremilast vs. Placebo at Week 16 102
Table 40: Apremilast SWOT Analysis, 2013 104
Table 41: Phase II Psoriasis Pipeline, 2013 105
Table 42: Phase I Psoriasis Pipeline, 2013 107
Table 43: Biosimilars Pipeline, 2013 110
Table 44: Sales Forecasts ($) for Psoriasis in the United States, 2012–2022 113
Table 45: Key Events Impacting Sales for Psoriasis in the United States, 2012–2022 115
Table 46: Psoriasis Market in the United States – Drivers and Barriers, 2012–2022 115
Table 47: Key Launch Dates 130
Table 48: Key Patent Expiries 130
Table 49: Physicians Surveyed, By Country 138

1.2 List of Figures

Figure 1: Psoriatic Plaque on Elbow of Patient 14
Figure 2: The Three Layers of the Skin and Associated Structures 16
Figure 3: Healthy Skin Versus Psoriatic Skin 17
Figure 4: BB-UVB Therapy Guidelines, According to the AAD 62
Figure 5: NB-UVB Therapy Guidelines, According to the AAD 62
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2012–2022 72
Figure 7: Estimated Sales of Biosimilars vs. Their Branded Counterparts in Psoriasis, 2012–2022 109
Figure 8: Sales for Psoriasis in the United States by Drug Class, 2012–2022 114